Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ProMIS Neurosciences Inc.PMN · Entity 6643 | See Remarks section. | July 25, 2025 | August 14, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ProMIS Neurosciences Inc.
Report date July 25, 2025 · Filed August 14, 2025 · Amendment
Amendment: balances below belong to this corrected disclosure, not necessarily a complete replacement of earlier positions.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Tranche A Common Share Purchase WarrantsSEC Table II · derivative / convertible security | IndirectSee footnote | 345,316 |
Reported balance
After 2025-07-25 transaction · row 1
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 1 · 2025-07-25 · Other · Disposed 119,800 · Balance 345,316 F1: On July 25, 2025, Title 19 Promis exercised 119,800 Tranche A purchase warrants, each exercisable to purchase one Common Share. These warrants were exercisable at an exercise price of $2.02 per warrant share; however, following an offer by Title 19 Promis and an acceptance by the Issuer, were exercised at an exercise price of $0.83518 per share. The remainder of these warrants are currently exercisable and expire on the earlier of (i) 18 months of the issue date and (ii) within 60 days of the public announcement via press release or the filing of a Current Report on Form 8-K of 6-month data from the cohorts treated with single ascending doses of PMN310. F2: This amendment is being filed to report that the price at which the Tranche A purchase warrants, Tranche B purchase warrants and Tranche C purchase warrants were exercised was inadvertently disclosed as $0.83158 instead of $0.83518. F3: By Title 19 Promis, a series of a Delaware limited liability company, of which the Reporting Person is the sole manager. |
| Tranche B Common Share Purchase WarrantsSEC Table II · derivative / convertible security | IndirectSee footnote | 345,316 |
Reported balance
After 2025-07-25 transaction · row 2
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 2 · 2025-07-25 · Other · Disposed 119,800 · Balance 345,316 F2: This amendment is being filed to report that the price at which the Tranche A purchase warrants, Tranche B purchase warrants and Tranche C purchase warrants were exercised was inadvertently disclosed as $0.83158 instead of $0.83518. F4: On July 25, 2025, Title 19 Promis exercised 119,800 Tranche B purchase warrants, each exercisable to purchase one Common Share. These warrants were exercisable at an exercise price of $2.02 per warrant share; however, following an offer by Title 19 Promis and an acceptance by the Issuer, were exercised at an exercise price of $0.83518 per share. The remainder of these warrants are currently exercisable and expire on the earlier of (i) 30 months of the issue date and (ii) within 60 days of the public announcement via press release or the filing of a Current Report on Form 8-K of 12-month data from the cohorts treated with single ascending doses of PMN310. F3: By Title 19 Promis, a series of a Delaware limited liability company, of which the Reporting Person is the sole manager. |
| Tranche C Common Share Purchase WarrantsSEC Table II · derivative / convertible security | IndirectSee footnote | 345,316 |
Reported balance
After 2025-07-25 transaction · row 3
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 3 · 2025-07-25 · Other · Disposed 119,800 · Balance 345,316 F2: This amendment is being filed to report that the price at which the Tranche A purchase warrants, Tranche B purchase warrants and Tranche C purchase warrants were exercised was inadvertently disclosed as $0.83158 instead of $0.83518. F5: On July 25, 2025, Title 19 Promis exercised 119,800 Tranche C purchase warrants, each exercisable to purchase one Common Share. These warrants were exercisable at an exercise price of $2.50 per warrant share; however, following an offer by Title 19 Promis and an acceptance by the Issuer, were exercised at an exercise price of $0.83518 per share. The remainder of these warrants are currently exercisable and expire on July 31, 2029. F3: By Title 19 Promis, a series of a Delaware limited liability company, of which the Reporting Person is the sole manager. |
Filing footnotes · ownership attribution and instrument terms
F1: On July 25, 2025, Title 19 Promis exercised 119,800 Tranche A purchase warrants, each exercisable to purchase one Common Share. These warrants were exercisable at an exercise price of $2.02 per warrant share; however, following an offer by Title 19 Promis and an acceptance by the Issuer, were exercised at an exercise price of $0.83518 per share. The remainder of these warrants are currently exercisable and expire on the earlier of (i) 18 months of the issue date and (ii) within 60 days of the public announcement via press release or the filing of a Current Report on Form 8-K of 6-month data from the cohorts treated with single ascending doses of PMN310.
F2: This amendment is being filed to report that the price at which the Tranche A purchase warrants, Tranche B purchase warrants and Tranche C purchase warrants were exercised was inadvertently disclosed as $0.83158 instead of $0.83518.
F3: By Title 19 Promis, a series of a Delaware limited liability company, of which the Reporting Person is the sole manager.
F4: On July 25, 2025, Title 19 Promis exercised 119,800 Tranche B purchase warrants, each exercisable to purchase one Common Share. These warrants were exercisable at an exercise price of $2.02 per warrant share; however, following an offer by Title 19 Promis and an acceptance by the Issuer, were exercised at an exercise price of $0.83518 per share. The remainder of these warrants are currently exercisable and expire on the earlier of (i) 30 months of the issue date and (ii) within 60 days of the public announcement via press release or the filing of a Current Report on Form 8-K of 12-month data from the cohorts treated with single ascending doses of PMN310.
F5: On July 25, 2025, Title 19 Promis exercised 119,800 Tranche C purchase warrants, each exercisable to purchase one Common Share. These warrants were exercisable at an exercise price of $2.50 per warrant share; however, following an offer by Title 19 Promis and an acceptance by the Issuer, were exercised at an exercise price of $0.83518 per share. The remainder of these warrants are currently exercisable and expire on July 31, 2029.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 29, 2025 Filed Jul 30, 2025 00:20 UTC | ProMIS Neurosciences Inc. PMN · Entity 6643 | PurchaseWarrants to Purchase Common Shares · Derivative | 539,100 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-25-071858 · tm2521929-2_4seq1.xml · derivative · entry 7 GORDON MICHAEL S · CIK 0001034608 · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 539,100 Underlying: Common Shares · 539,100 shares Expires not disclosed F5 · derivative.exercise_price: On July 29, 2025, Title 19 Promis acquired 539,100 warrants, each exercisable to purchase one Common Share, at an exercise price of $1.25 per share. The purchase price for each warrant was $0.1875 per share. The warrants are currently exercisable and expire five years after the date of issuance. F5 · price: On July 29, 2025, Title 19 Promis acquired 539,100 warrants, each exercisable to purchase one Common Share, at an exercise price of $1.25 per share. The purchase price for each warrant was $0.1875 per share. The warrants are currently exercisable and expire five years after the date of issuance. F5 · derivative.exercise_date: On July 29, 2025, Title 19 Promis acquired 539,100 warrants, each exercisable to purchase one Common Share, at an exercise price of $1.25 per share. The purchase price for each warrant was $0.1875 per share. The warrants are currently exercisable and expire five years after the date of issuance. F5 · derivative.expiration_date: On July 29, 2025, Title 19 Promis acquired 539,100 warrants, each exercisable to purchase one Common Share, at an exercise price of $1.25 per share. The purchase price for each warrant was $0.1875 per share. The warrants are currently exercisable and expire five years after the date of issuance. F2 · ownership.nature: By Title 19 Promis, a series of a Delaware limited liability company, of which the Reporting Person is the sole manager. Read SEC document |
| July 25, 2025 Filed Jul 30, 2025 00:20 UTC | ProMIS Neurosciences Inc. PMN · Entity 6643 | OtherTranche C Common Share Purchase Warrants · Derivative | 119,800 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-25-071858 · tm2521929-2_4seq1.xml · derivative · entry 6 GORDON MICHAEL S · CIK 0001034608 · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 345,316 Underlying: Common Shares · 119,800 shares Expires not disclosed F4 · derivative.exercise_price: On July 25, 2025, Title 19 Promis exercised 119,800 Tranche C purchase warrants, each exercisable to purchase one Common Share. These warrants were exercisable at an exercise price of $2.50 per warrant share; however, following an offer by Title 19 Promis and an acceptance by the Issuer, were exercised at an exercise price of $0.83158 per share. The remainder of these warrants are currently exercisable and expire on July 31, 2029. F4 · derivative.exercise_date: On July 25, 2025, Title 19 Promis exercised 119,800 Tranche C purchase warrants, each exercisable to purchase one Common Share. These warrants were exercisable at an exercise price of $2.50 per warrant share; however, following an offer by Title 19 Promis and an acceptance by the Issuer, were exercised at an exercise price of $0.83158 per share. The remainder of these warrants are currently exercisable and expire on July 31, 2029. F4 · derivative.expiration_date: On July 25, 2025, Title 19 Promis exercised 119,800 Tranche C purchase warrants, each exercisable to purchase one Common Share. These warrants were exercisable at an exercise price of $2.50 per warrant share; however, following an offer by Title 19 Promis and an acceptance by the Issuer, were exercised at an exercise price of $0.83158 per share. The remainder of these warrants are currently exercisable and expire on July 31, 2029. F2 · ownership.nature: By Title 19 Promis, a series of a Delaware limited liability company, of which the Reporting Person is the sole manager. Read SEC document |
| July 25, 2025 Filed Jul 30, 2025 00:20 UTC | ProMIS Neurosciences Inc. PMN · Entity 6643 | OtherTranche B Common Share Purchase Warrants · Derivative | 119,800 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-25-071858 · tm2521929-2_4seq1.xml · derivative · entry 5 GORDON MICHAEL S · CIK 0001034608 · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 345,316 Underlying: Common Shares · 119,800 shares Expires not disclosed F3 · derivative.exercise_price: On July 25, 2025, Title 19 Promis exercised 119,800 Tranche B purchase warrants, each exercisable to purchase one Common Share. These warrants were exercisable at an exercise price of $2.02 per warrant share; however, following an offer by Title 19 Promis and an acceptance by the Issuer, were exercised at an exercise price of $0.83158 per share. The remainder of these warrants are currently exercisable and expire on the earlier of (i) 30 months of the issue date and (ii) within 60 days of the public announcement via press release or the filing of a Current Report on Form 8-K of 12-month data from the cohorts treated with single ascending doses of PMN310. F3 · derivative.exercise_date: On July 25, 2025, Title 19 Promis exercised 119,800 Tranche B purchase warrants, each exercisable to purchase one Common Share. These warrants were exercisable at an exercise price of $2.02 per warrant share; however, following an offer by Title 19 Promis and an acceptance by the Issuer, were exercised at an exercise price of $0.83158 per share. The remainder of these warrants are currently exercisable and expire on the earlier of (i) 30 months of the issue date and (ii) within 60 days of the public announcement via press release or the filing of a Current Report on Form 8-K of 12-month data from the cohorts treated with single ascending doses of PMN310. F3 · derivative.expiration_date: On July 25, 2025, Title 19 Promis exercised 119,800 Tranche B purchase warrants, each exercisable to purchase one Common Share. These warrants were exercisable at an exercise price of $2.02 per warrant share; however, following an offer by Title 19 Promis and an acceptance by the Issuer, were exercised at an exercise price of $0.83158 per share. The remainder of these warrants are currently exercisable and expire on the earlier of (i) 30 months of the issue date and (ii) within 60 days of the public announcement via press release or the filing of a Current Report on Form 8-K of 12-month data from the cohorts treated with single ascending doses of PMN310. F2 · ownership.nature: By Title 19 Promis, a series of a Delaware limited liability company, of which the Reporting Person is the sole manager. Read SEC document |
| July 25, 2025 Filed Jul 30, 2025 00:20 UTC | ProMIS Neurosciences Inc. PMN · Entity 6643 | OtherTranche A Common Share Purchase Warrants · Derivative | 119,800 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-25-071858 · tm2521929-2_4seq1.xml · derivative · entry 4 GORDON MICHAEL S · CIK 0001034608 · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 345,316 Underlying: Common Shares · 119,800 shares Expires not disclosed F1 · derivative.exercise_price: On July 25, 2025, Title 19 Promis exercised 119,800 Tranche A purchase warrants, each exercisable to purchase one Common Share. These warrants were exercisable at an exercise price of $2.02 per warrant share; however, following an offer by Title 19 Promis and an acceptance by the Issuer, were exercised at an exercise price of $0.83158 per share. The remainder of these warrants are currently exercisable and expire on the earlier of (i) 18 months of the issue date and (ii) within 60 days of the public announcement via press release or the filing of a Current Report on Form 8-K of 6-month data from the cohorts treated with single ascending doses of PMN310. F1 · derivative.exercise_date: On July 25, 2025, Title 19 Promis exercised 119,800 Tranche A purchase warrants, each exercisable to purchase one Common Share. These warrants were exercisable at an exercise price of $2.02 per warrant share; however, following an offer by Title 19 Promis and an acceptance by the Issuer, were exercised at an exercise price of $0.83158 per share. The remainder of these warrants are currently exercisable and expire on the earlier of (i) 18 months of the issue date and (ii) within 60 days of the public announcement via press release or the filing of a Current Report on Form 8-K of 6-month data from the cohorts treated with single ascending doses of PMN310. F1 · derivative.expiration_date: On July 25, 2025, Title 19 Promis exercised 119,800 Tranche A purchase warrants, each exercisable to purchase one Common Share. These warrants were exercisable at an exercise price of $2.02 per warrant share; however, following an offer by Title 19 Promis and an acceptance by the Issuer, were exercised at an exercise price of $0.83158 per share. The remainder of these warrants are currently exercisable and expire on the earlier of (i) 18 months of the issue date and (ii) within 60 days of the public announcement via press release or the filing of a Current Report on Form 8-K of 6-month data from the cohorts treated with single ascending doses of PMN310. F2 · ownership.nature: By Title 19 Promis, a series of a Delaware limited liability company, of which the Reporting Person is the sole manager. Read SEC document |
| July 25, 2025 Filed Jul 30, 2025 00:20 UTC | ProMIS Neurosciences Inc. PMN · Entity 6643 | OtherCommon Shares, no par value | 119,800 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-25-071858 · tm2521929-2_4seq1.xml · nonDerivative · entry 3 GORDON MICHAEL S · CIK 0001034608 · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By Title 19 Promis Disclosed balance after: 2,435,029 F4 · kind: On July 25, 2025, Title 19 Promis exercised 119,800 Tranche C purchase warrants, each exercisable to purchase one Common Share. These warrants were exercisable at an exercise price of $2.50 per warrant share; however, following an offer by Title 19 Promis and an acceptance by the Issuer, were exercised at an exercise price of $0.83158 per share. The remainder of these warrants are currently exercisable and expire on July 31, 2029. F4 · price: On July 25, 2025, Title 19 Promis exercised 119,800 Tranche C purchase warrants, each exercisable to purchase one Common Share. These warrants were exercisable at an exercise price of $2.50 per warrant share; however, following an offer by Title 19 Promis and an acceptance by the Issuer, were exercised at an exercise price of $0.83158 per share. The remainder of these warrants are currently exercisable and expire on July 31, 2029. F2 · ownership.nature: By Title 19 Promis, a series of a Delaware limited liability company, of which the Reporting Person is the sole manager. Read SEC document |
| July 25, 2025 Filed Jul 30, 2025 00:20 UTC | ProMIS Neurosciences Inc. PMN · Entity 6643 | OtherCommon Shares, no par value | 119,800 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-25-071858 · tm2521929-2_4seq1.xml · nonDerivative · entry 2 GORDON MICHAEL S · CIK 0001034608 · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By Title 19 Promis Disclosed balance after: 2,315,229 F3 · kind: On July 25, 2025, Title 19 Promis exercised 119,800 Tranche B purchase warrants, each exercisable to purchase one Common Share. These warrants were exercisable at an exercise price of $2.02 per warrant share; however, following an offer by Title 19 Promis and an acceptance by the Issuer, were exercised at an exercise price of $0.83158 per share. The remainder of these warrants are currently exercisable and expire on the earlier of (i) 30 months of the issue date and (ii) within 60 days of the public announcement via press release or the filing of a Current Report on Form 8-K of 12-month data from the cohorts treated with single ascending doses of PMN310. F3 · price: On July 25, 2025, Title 19 Promis exercised 119,800 Tranche B purchase warrants, each exercisable to purchase one Common Share. These warrants were exercisable at an exercise price of $2.02 per warrant share; however, following an offer by Title 19 Promis and an acceptance by the Issuer, were exercised at an exercise price of $0.83158 per share. The remainder of these warrants are currently exercisable and expire on the earlier of (i) 30 months of the issue date and (ii) within 60 days of the public announcement via press release or the filing of a Current Report on Form 8-K of 12-month data from the cohorts treated with single ascending doses of PMN310. F2 · ownership.nature: By Title 19 Promis, a series of a Delaware limited liability company, of which the Reporting Person is the sole manager. Read SEC document |
| July 25, 2025 Filed Jul 30, 2025 00:20 UTC | ProMIS Neurosciences Inc. PMN · Entity 6643 | OtherCommon Shares, no par value | 119,800 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-25-071858 · tm2521929-2_4seq1.xml · nonDerivative · entry 1 GORDON MICHAEL S · CIK 0001034608 · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By Title 19 Promis Disclosed balance after: 2,195,429 F1 · kind: On July 25, 2025, Title 19 Promis exercised 119,800 Tranche A purchase warrants, each exercisable to purchase one Common Share. These warrants were exercisable at an exercise price of $2.02 per warrant share; however, following an offer by Title 19 Promis and an acceptance by the Issuer, were exercised at an exercise price of $0.83158 per share. The remainder of these warrants are currently exercisable and expire on the earlier of (i) 18 months of the issue date and (ii) within 60 days of the public announcement via press release or the filing of a Current Report on Form 8-K of 6-month data from the cohorts treated with single ascending doses of PMN310. F1 · price: On July 25, 2025, Title 19 Promis exercised 119,800 Tranche A purchase warrants, each exercisable to purchase one Common Share. These warrants were exercisable at an exercise price of $2.02 per warrant share; however, following an offer by Title 19 Promis and an acceptance by the Issuer, were exercised at an exercise price of $0.83158 per share. The remainder of these warrants are currently exercisable and expire on the earlier of (i) 18 months of the issue date and (ii) within 60 days of the public announcement via press release or the filing of a Current Report on Form 8-K of 6-month data from the cohorts treated with single ascending doses of PMN310. F2 · ownership.nature: By Title 19 Promis, a series of a Delaware limited liability company, of which the Reporting Person is the sole manager. Read SEC document |
| July 25, 2025 Filed Aug 14, 2025 20:17 UTC Amendment | ProMIS Neurosciences Inc. PMN · Entity 6643 | OtherTranche C Common Share Purchase Warrants · Derivative | 119,800 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-25-078631 · tm2523440-4_4aseq1.xml · derivative · entry 3 GORDON MICHAEL S · CIK 0001034608 · See Remarks section. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 345,316 Underlying: Common Shares · 119,800 shares Expires not disclosed F2 · derivative.exercise_price: This amendment is being filed to report that the price at which the Tranche A purchase warrants, Tranche B purchase warrants and Tranche C purchase warrants were exercised was inadvertently disclosed as $0.83158 instead of $0.83518. F5 · derivative.exercise_price: On July 25, 2025, Title 19 Promis exercised 119,800 Tranche C purchase warrants, each exercisable to purchase one Common Share. These warrants were exercisable at an exercise price of $2.50 per warrant share; however, following an offer by Title 19 Promis and an acceptance by the Issuer, were exercised at an exercise price of $0.83518 per share. The remainder of these warrants are currently exercisable and expire on July 31, 2029. F5 · derivative.exercise_date: On July 25, 2025, Title 19 Promis exercised 119,800 Tranche C purchase warrants, each exercisable to purchase one Common Share. These warrants were exercisable at an exercise price of $2.50 per warrant share; however, following an offer by Title 19 Promis and an acceptance by the Issuer, were exercised at an exercise price of $0.83518 per share. The remainder of these warrants are currently exercisable and expire on July 31, 2029. F5 · derivative.expiration_date: On July 25, 2025, Title 19 Promis exercised 119,800 Tranche C purchase warrants, each exercisable to purchase one Common Share. These warrants were exercisable at an exercise price of $2.50 per warrant share; however, following an offer by Title 19 Promis and an acceptance by the Issuer, were exercised at an exercise price of $0.83518 per share. The remainder of these warrants are currently exercisable and expire on July 31, 2029. F3 · ownership.nature: By Title 19 Promis, a series of a Delaware limited liability company, of which the Reporting Person is the sole manager. Read SEC document |
| July 25, 2025 Filed Aug 14, 2025 20:17 UTC Amendment | ProMIS Neurosciences Inc. PMN · Entity 6643 | OtherTranche B Common Share Purchase Warrants · Derivative | 119,800 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-25-078631 · tm2523440-4_4aseq1.xml · derivative · entry 2 GORDON MICHAEL S · CIK 0001034608 · See Remarks section. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 345,316 Underlying: Common Shares · 119,800 shares Expires not disclosed F2 · derivative.exercise_price: This amendment is being filed to report that the price at which the Tranche A purchase warrants, Tranche B purchase warrants and Tranche C purchase warrants were exercised was inadvertently disclosed as $0.83158 instead of $0.83518. F4 · derivative.exercise_price: On July 25, 2025, Title 19 Promis exercised 119,800 Tranche B purchase warrants, each exercisable to purchase one Common Share. These warrants were exercisable at an exercise price of $2.02 per warrant share; however, following an offer by Title 19 Promis and an acceptance by the Issuer, were exercised at an exercise price of $0.83518 per share. The remainder of these warrants are currently exercisable and expire on the earlier of (i) 30 months of the issue date and (ii) within 60 days of the public announcement via press release or the filing of a Current Report on Form 8-K of 12-month data from the cohorts treated with single ascending doses of PMN310. F4 · derivative.exercise_date: On July 25, 2025, Title 19 Promis exercised 119,800 Tranche B purchase warrants, each exercisable to purchase one Common Share. These warrants were exercisable at an exercise price of $2.02 per warrant share; however, following an offer by Title 19 Promis and an acceptance by the Issuer, were exercised at an exercise price of $0.83518 per share. The remainder of these warrants are currently exercisable and expire on the earlier of (i) 30 months of the issue date and (ii) within 60 days of the public announcement via press release or the filing of a Current Report on Form 8-K of 12-month data from the cohorts treated with single ascending doses of PMN310. F4 · derivative.expiration_date: On July 25, 2025, Title 19 Promis exercised 119,800 Tranche B purchase warrants, each exercisable to purchase one Common Share. These warrants were exercisable at an exercise price of $2.02 per warrant share; however, following an offer by Title 19 Promis and an acceptance by the Issuer, were exercised at an exercise price of $0.83518 per share. The remainder of these warrants are currently exercisable and expire on the earlier of (i) 30 months of the issue date and (ii) within 60 days of the public announcement via press release or the filing of a Current Report on Form 8-K of 12-month data from the cohorts treated with single ascending doses of PMN310. F3 · ownership.nature: By Title 19 Promis, a series of a Delaware limited liability company, of which the Reporting Person is the sole manager. Read SEC document |
| July 25, 2025 Filed Aug 14, 2025 20:17 UTC Amendment | ProMIS Neurosciences Inc. PMN · Entity 6643 | OtherTranche A Common Share Purchase Warrants · Derivative | 119,800 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-25-078631 · tm2523440-4_4aseq1.xml · derivative · entry 1 GORDON MICHAEL S · CIK 0001034608 · See Remarks section. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 345,316 Underlying: Common Shares · 119,800 shares Expires not disclosed F1 · derivative.exercise_price: On July 25, 2025, Title 19 Promis exercised 119,800 Tranche A purchase warrants, each exercisable to purchase one Common Share. These warrants were exercisable at an exercise price of $2.02 per warrant share; however, following an offer by Title 19 Promis and an acceptance by the Issuer, were exercised at an exercise price of $0.83518 per share. The remainder of these warrants are currently exercisable and expire on the earlier of (i) 18 months of the issue date and (ii) within 60 days of the public announcement via press release or the filing of a Current Report on Form 8-K of 6-month data from the cohorts treated with single ascending doses of PMN310. F2 · derivative.exercise_price: This amendment is being filed to report that the price at which the Tranche A purchase warrants, Tranche B purchase warrants and Tranche C purchase warrants were exercised was inadvertently disclosed as $0.83158 instead of $0.83518. F1 · derivative.exercise_date: On July 25, 2025, Title 19 Promis exercised 119,800 Tranche A purchase warrants, each exercisable to purchase one Common Share. These warrants were exercisable at an exercise price of $2.02 per warrant share; however, following an offer by Title 19 Promis and an acceptance by the Issuer, were exercised at an exercise price of $0.83518 per share. The remainder of these warrants are currently exercisable and expire on the earlier of (i) 18 months of the issue date and (ii) within 60 days of the public announcement via press release or the filing of a Current Report on Form 8-K of 6-month data from the cohorts treated with single ascending doses of PMN310. F1 · derivative.expiration_date: On July 25, 2025, Title 19 Promis exercised 119,800 Tranche A purchase warrants, each exercisable to purchase one Common Share. These warrants were exercisable at an exercise price of $2.02 per warrant share; however, following an offer by Title 19 Promis and an acceptance by the Issuer, were exercised at an exercise price of $0.83518 per share. The remainder of these warrants are currently exercisable and expire on the earlier of (i) 18 months of the issue date and (ii) within 60 days of the public announcement via press release or the filing of a Current Report on Form 8-K of 6-month data from the cohorts treated with single ascending doses of PMN310. F3 · ownership.nature: By Title 19 Promis, a series of a Delaware limited liability company, of which the Reporting Person is the sole manager. Read SEC document |
| June 30, 2025 Filed Jul 2, 2025 20:15 UTC | ProMIS Neurosciences Inc. PMN · Entity 6643 | SaleCommon Shares, no par value | 93,223 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-25-065292 · tm2519639-1_4seq1.xml · nonDerivative · entry 1 GORDON MICHAEL S · CIK 0001034608 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · price: On June 30, 2025, the reporting person contributed 93,223 shares of common stock of the Issuer held by the reporting person to Skye Peak Partners LLC, a Delaware limited liability company ("SPP"), in exchange for membership interests of SPP. Read SEC document |
| March 13, 2025 Filed Aug 14, 2025 20:15 UTC | ProMIS Neurosciences Inc. PMN · Entity 6643 | OtherCommon Shares, no par value | 48,333 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-25-078615 · tm2523440-2_4seq1.xml · nonDerivative · entry 1 GORDON MICHAEL S · CIK 0001034608 · See Remarks section. 10b5-1 filing: No plan indicated Ownership: Indirect · By Title 19 Acies Disclosed balance after: 0 F1 · kind: On March 13, 2025, the ownership of Title 19 Acies, a series of a Delaware limited liability company, was assigned to Skye Peak Partners LLC, a Delaware limited liability company ("SPP"), effective as of January 1, 2025. In connection with such assignment, the management of Title 19 Acies changed from the Reporting Person as sole manager to Emmett Gordon and Michael Youniss as managers, and the Reporting Person does not otherwise have investment control over the shares of the Issuer held by SPP. Accordingly, the Reporting Person no longer has a pecuniary interest in shares of the Issuer held by Title 19 Acies. F1 · price: On March 13, 2025, the ownership of Title 19 Acies, a series of a Delaware limited liability company, was assigned to Skye Peak Partners LLC, a Delaware limited liability company ("SPP"), effective as of January 1, 2025. In connection with such assignment, the management of Title 19 Acies changed from the Reporting Person as sole manager to Emmett Gordon and Michael Youniss as managers, and the Reporting Person does not otherwise have investment control over the shares of the Issuer held by SPP. Accordingly, the Reporting Person no longer has a pecuniary interest in shares of the Issuer held by Title 19 Acies. F2 · ownership.nature: By Title 19 Acies, of which the Reporting Person was the sole manager. Read SEC document |
| September 17, 2024 Filed Sep 18, 2024 20:15 UTC | ProMIS Neurosciences Inc. PMN · Entity 6643 | PurchaseCommon Shares, no par value | 16,292 | $1.40 | $22,808.80 |
DisclosureSEC source: 0001104659-24-100976 · tm2424268-1_4seq1.xml · nonDerivative · entry 2 GORDON MICHAEL S · CIK 0001034608 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 93,223 F2 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in four separate transactions, with prices ranging from $1.37 to $1.40 for an average weighted purchase price of $1.40. The reporting person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares purchased in each transaction. Read SEC document |
| September 16, 2024 Filed Sep 18, 2024 20:15 UTC | ProMIS Neurosciences Inc. PMN · Entity 6643 | PurchaseCommon Shares, no par value | 76,931 | $1.22 | $94,071.23 |
DisclosureSEC source: 0001104659-24-100976 · tm2424268-1_4seq1.xml · nonDerivative · entry 1 GORDON MICHAEL S · CIK 0001034608 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 76,931 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in forty-two separate transactions, with prices ranging from $1.1200 to $1.3700 for an average weighted purchase price of $1.2228 rounded to the nearest ten thousandth. The reporting person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares purchased in each transaction. Read SEC document |
| July 31, 2024 Filed Aug 2, 2024 20:15 UTC | ProMIS Neurosciences Inc. PMN · Entity 6643 | ConversionSeries 2 Preferred Shares, no par value · Derivative | 500,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-24-085371 · tm2420441-1_4seq1.xml · derivative · entry 7 GORDON MICHAEL S · CIK 0001034608 · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Shares · 500,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: The Series 2 Preferred Shares involuntarily converted into Common Shares at a 1:1 ratio upon the closing of the Offering, which was a cumulative qualified equity financing in excess of $14 million. F3 · price: The Series 2 Preferred Shares involuntarily converted into Common Shares at a 1:1 ratio upon the closing of the Offering, which was a cumulative qualified equity financing in excess of $14 million. F3 · derivative.exercise_date: The Series 2 Preferred Shares involuntarily converted into Common Shares at a 1:1 ratio upon the closing of the Offering, which was a cumulative qualified equity financing in excess of $14 million. F3 · derivative.expiration_date: The Series 2 Preferred Shares involuntarily converted into Common Shares at a 1:1 ratio upon the closing of the Offering, which was a cumulative qualified equity financing in excess of $14 million. F2 · ownership.nature: By Title 19 Promis, a series of a Delaware limited liability company, of which the Reporting Person is the sole manager. Read SEC document |
| July 31, 2024 Filed Aug 2, 2024 20:15 UTC | ProMIS Neurosciences Inc. PMN · Entity 6643 | PurchaseTranche C Common Share Purchase Warrants · Derivative | 465,116 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-24-085371 · tm2420441-1_4seq1.xml · derivative · entry 6 GORDON MICHAEL S · CIK 0001034608 · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 465,116 Underlying: Common Shares · 465,116 shares Expires not disclosed F1 · derivative.exercise_price: On July 31, 2024, Title 19 Promis acquired 465,116 units, each consisting of (a) one Common Share, (b) one Tranche A Common Share purchase warrant, (c) one Tranche B Common Share purchase warrant and (iv) one Tranche C Common Share purchase warrant, in a private placement the ("Offering") conducted by the Issuer. The purchase price for each Unit was $2.15 per Unit. F7 · derivative.exercise_price: Consists of 465,116 Tranche C purchase warrants, each exercisable to purchase one Common Share at an exercise price of $2.50 per warrant share. These warrants are currently exercisable and expire on July 31, 2029. F1 · price: On July 31, 2024, Title 19 Promis acquired 465,116 units, each consisting of (a) one Common Share, (b) one Tranche A Common Share purchase warrant, (c) one Tranche B Common Share purchase warrant and (iv) one Tranche C Common Share purchase warrant, in a private placement the ("Offering") conducted by the Issuer. The purchase price for each Unit was $2.15 per Unit. F7 · price: Consists of 465,116 Tranche C purchase warrants, each exercisable to purchase one Common Share at an exercise price of $2.50 per warrant share. These warrants are currently exercisable and expire on July 31, 2029. F1 · derivative.exercise_date: On July 31, 2024, Title 19 Promis acquired 465,116 units, each consisting of (a) one Common Share, (b) one Tranche A Common Share purchase warrant, (c) one Tranche B Common Share purchase warrant and (iv) one Tranche C Common Share purchase warrant, in a private placement the ("Offering") conducted by the Issuer. The purchase price for each Unit was $2.15 per Unit. F7 · derivative.exercise_date: Consists of 465,116 Tranche C purchase warrants, each exercisable to purchase one Common Share at an exercise price of $2.50 per warrant share. These warrants are currently exercisable and expire on July 31, 2029. F1 · derivative.expiration_date: On July 31, 2024, Title 19 Promis acquired 465,116 units, each consisting of (a) one Common Share, (b) one Tranche A Common Share purchase warrant, (c) one Tranche B Common Share purchase warrant and (iv) one Tranche C Common Share purchase warrant, in a private placement the ("Offering") conducted by the Issuer. The purchase price for each Unit was $2.15 per Unit. F7 · derivative.expiration_date: Consists of 465,116 Tranche C purchase warrants, each exercisable to purchase one Common Share at an exercise price of $2.50 per warrant share. These warrants are currently exercisable and expire on July 31, 2029. F2 · ownership.nature: By Title 19 Promis, a series of a Delaware limited liability company, of which the Reporting Person is the sole manager. Read SEC document |
| July 31, 2024 Filed Aug 2, 2024 20:15 UTC | ProMIS Neurosciences Inc. PMN · Entity 6643 | PurchaseTranche B Common Share Purchase Warrants · Derivative | 465,116 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-24-085371 · tm2420441-1_4seq1.xml · derivative · entry 5 GORDON MICHAEL S · CIK 0001034608 · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 465,116 Underlying: Common Shares · 465,116 shares Expires not disclosed F1 · derivative.exercise_price: On July 31, 2024, Title 19 Promis acquired 465,116 units, each consisting of (a) one Common Share, (b) one Tranche A Common Share purchase warrant, (c) one Tranche B Common Share purchase warrant and (iv) one Tranche C Common Share purchase warrant, in a private placement the ("Offering") conducted by the Issuer. The purchase price for each Unit was $2.15 per Unit. F6 · derivative.exercise_price: Consists of 465,116 Tranche B purchase warrants, each exercisable to purchase one Common Share at an exercise price of $2.02 per warrant share. These warrants are immediately exercisable beginning on the date that such approval as may be required by the applicable rules and regulations of the Nasdaq Stock Market LLC (or any successor entity) from the shareholders of the Issuer with respect to the issuance of the Tranche B purchase warrants and the Common Shares upon the exercise thereof is received and deemed effective under Ontario law. These warrants expire on the earlier of (i) 30 months and (ii) within 60 days of the public announcement via press release or the filing of a Current Report on Form 8-K of 12-month data from the cohorts treated with single ascending doses of PMN310. F1 · price: On July 31, 2024, Title 19 Promis acquired 465,116 units, each consisting of (a) one Common Share, (b) one Tranche A Common Share purchase warrant, (c) one Tranche B Common Share purchase warrant and (iv) one Tranche C Common Share purchase warrant, in a private placement the ("Offering") conducted by the Issuer. The purchase price for each Unit was $2.15 per Unit. F6 · price: Consists of 465,116 Tranche B purchase warrants, each exercisable to purchase one Common Share at an exercise price of $2.02 per warrant share. These warrants are immediately exercisable beginning on the date that such approval as may be required by the applicable rules and regulations of the Nasdaq Stock Market LLC (or any successor entity) from the shareholders of the Issuer with respect to the issuance of the Tranche B purchase warrants and the Common Shares upon the exercise thereof is received and deemed effective under Ontario law. These warrants expire on the earlier of (i) 30 months and (ii) within 60 days of the public announcement via press release or the filing of a Current Report on Form 8-K of 12-month data from the cohorts treated with single ascending doses of PMN310. F1 · derivative.exercise_date: On July 31, 2024, Title 19 Promis acquired 465,116 units, each consisting of (a) one Common Share, (b) one Tranche A Common Share purchase warrant, (c) one Tranche B Common Share purchase warrant and (iv) one Tranche C Common Share purchase warrant, in a private placement the ("Offering") conducted by the Issuer. The purchase price for each Unit was $2.15 per Unit. F6 · derivative.exercise_date: Consists of 465,116 Tranche B purchase warrants, each exercisable to purchase one Common Share at an exercise price of $2.02 per warrant share. These warrants are immediately exercisable beginning on the date that such approval as may be required by the applicable rules and regulations of the Nasdaq Stock Market LLC (or any successor entity) from the shareholders of the Issuer with respect to the issuance of the Tranche B purchase warrants and the Common Shares upon the exercise thereof is received and deemed effective under Ontario law. These warrants expire on the earlier of (i) 30 months and (ii) within 60 days of the public announcement via press release or the filing of a Current Report on Form 8-K of 12-month data from the cohorts treated with single ascending doses of PMN310. F1 · derivative.expiration_date: On July 31, 2024, Title 19 Promis acquired 465,116 units, each consisting of (a) one Common Share, (b) one Tranche A Common Share purchase warrant, (c) one Tranche B Common Share purchase warrant and (iv) one Tranche C Common Share purchase warrant, in a private placement the ("Offering") conducted by the Issuer. The purchase price for each Unit was $2.15 per Unit. F6 · derivative.expiration_date: Consists of 465,116 Tranche B purchase warrants, each exercisable to purchase one Common Share at an exercise price of $2.02 per warrant share. These warrants are immediately exercisable beginning on the date that such approval as may be required by the applicable rules and regulations of the Nasdaq Stock Market LLC (or any successor entity) from the shareholders of the Issuer with respect to the issuance of the Tranche B purchase warrants and the Common Shares upon the exercise thereof is received and deemed effective under Ontario law. These warrants expire on the earlier of (i) 30 months and (ii) within 60 days of the public announcement via press release or the filing of a Current Report on Form 8-K of 12-month data from the cohorts treated with single ascending doses of PMN310. F2 · ownership.nature: By Title 19 Promis, a series of a Delaware limited liability company, of which the Reporting Person is the sole manager. Read SEC document |
| July 31, 2024 Filed Aug 2, 2024 20:15 UTC | ProMIS Neurosciences Inc. PMN · Entity 6643 | PurchaseTranche A Common Share Purchase Warrants · Derivative | 465,116 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-24-085371 · tm2420441-1_4seq1.xml · derivative · entry 4 GORDON MICHAEL S · CIK 0001034608 · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 465,116 Underlying: Common Shares · 465,116 shares Expires not disclosed F1 · derivative.exercise_price: On July 31, 2024, Title 19 Promis acquired 465,116 units, each consisting of (a) one Common Share, (b) one Tranche A Common Share purchase warrant, (c) one Tranche B Common Share purchase warrant and (iv) one Tranche C Common Share purchase warrant, in a private placement the ("Offering") conducted by the Issuer. The purchase price for each Unit was $2.15 per Unit. F5 · derivative.exercise_price: Consists of 465,116 Tranche A purchase warrants, each exercisable to purchase one Common Share at an exercise price of $2.02 per warrant share. These warrants are immediately exercisable beginning on the date that approval as may be required by the applicable rules and regulations of the Nasdaq Stock Market LLC (or any successor entity) from the shareholders of the Issuer with respect to the issuance of the Tranche A purchase warrants and the Common Shares upon the exercise thereof is received and deemed effective under Ontario law. These warrants expire on the earlier of (i) 18 months and (ii) within 60 days of the public announcement via press release or the filing of a Current Report on Form 8-K of 6-month data from the cohorts treated with single ascending doses of PMN310. F1 · price: On July 31, 2024, Title 19 Promis acquired 465,116 units, each consisting of (a) one Common Share, (b) one Tranche A Common Share purchase warrant, (c) one Tranche B Common Share purchase warrant and (iv) one Tranche C Common Share purchase warrant, in a private placement the ("Offering") conducted by the Issuer. The purchase price for each Unit was $2.15 per Unit. F5 · price: Consists of 465,116 Tranche A purchase warrants, each exercisable to purchase one Common Share at an exercise price of $2.02 per warrant share. These warrants are immediately exercisable beginning on the date that approval as may be required by the applicable rules and regulations of the Nasdaq Stock Market LLC (or any successor entity) from the shareholders of the Issuer with respect to the issuance of the Tranche A purchase warrants and the Common Shares upon the exercise thereof is received and deemed effective under Ontario law. These warrants expire on the earlier of (i) 18 months and (ii) within 60 days of the public announcement via press release or the filing of a Current Report on Form 8-K of 6-month data from the cohorts treated with single ascending doses of PMN310. F1 · derivative.exercise_date: On July 31, 2024, Title 19 Promis acquired 465,116 units, each consisting of (a) one Common Share, (b) one Tranche A Common Share purchase warrant, (c) one Tranche B Common Share purchase warrant and (iv) one Tranche C Common Share purchase warrant, in a private placement the ("Offering") conducted by the Issuer. The purchase price for each Unit was $2.15 per Unit. F5 · derivative.exercise_date: Consists of 465,116 Tranche A purchase warrants, each exercisable to purchase one Common Share at an exercise price of $2.02 per warrant share. These warrants are immediately exercisable beginning on the date that approval as may be required by the applicable rules and regulations of the Nasdaq Stock Market LLC (or any successor entity) from the shareholders of the Issuer with respect to the issuance of the Tranche A purchase warrants and the Common Shares upon the exercise thereof is received and deemed effective under Ontario law. These warrants expire on the earlier of (i) 18 months and (ii) within 60 days of the public announcement via press release or the filing of a Current Report on Form 8-K of 6-month data from the cohorts treated with single ascending doses of PMN310. F1 · derivative.expiration_date: On July 31, 2024, Title 19 Promis acquired 465,116 units, each consisting of (a) one Common Share, (b) one Tranche A Common Share purchase warrant, (c) one Tranche B Common Share purchase warrant and (iv) one Tranche C Common Share purchase warrant, in a private placement the ("Offering") conducted by the Issuer. The purchase price for each Unit was $2.15 per Unit. F5 · derivative.expiration_date: Consists of 465,116 Tranche A purchase warrants, each exercisable to purchase one Common Share at an exercise price of $2.02 per warrant share. These warrants are immediately exercisable beginning on the date that approval as may be required by the applicable rules and regulations of the Nasdaq Stock Market LLC (or any successor entity) from the shareholders of the Issuer with respect to the issuance of the Tranche A purchase warrants and the Common Shares upon the exercise thereof is received and deemed effective under Ontario law. These warrants expire on the earlier of (i) 18 months and (ii) within 60 days of the public announcement via press release or the filing of a Current Report on Form 8-K of 6-month data from the cohorts treated with single ascending doses of PMN310. F2 · ownership.nature: By Title 19 Promis, a series of a Delaware limited liability company, of which the Reporting Person is the sole manager. Read SEC document |
| July 31, 2024 Filed Aug 2, 2024 20:15 UTC | ProMIS Neurosciences Inc. PMN · Entity 6643 | ConversionCommon Shares, no par value | 500,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-24-085371 · tm2420441-1_4seq1.xml · nonDerivative · entry 2 GORDON MICHAEL S · CIK 0001034608 · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By Title 19 Promis Disclosed balance after: 2,075,629 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · kind: The Series 2 Preferred Shares involuntarily converted into Common Shares at a 1:1 ratio upon the closing of the Offering, which was a cumulative qualified equity financing in excess of $14 million. F3 · price: The Series 2 Preferred Shares involuntarily converted into Common Shares at a 1:1 ratio upon the closing of the Offering, which was a cumulative qualified equity financing in excess of $14 million. F2 · ownership.nature: By Title 19 Promis, a series of a Delaware limited liability company, of which the Reporting Person is the sole manager. Read SEC document |
| July 31, 2024 Filed Aug 2, 2024 20:15 UTC | ProMIS Neurosciences Inc. PMN · Entity 6643 | PurchaseCommon Shares, no par value | 465,116 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-24-085371 · tm2420441-1_4seq1.xml · nonDerivative · entry 1 GORDON MICHAEL S · CIK 0001034608 · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By Title 19 Promis Disclosed balance after: 1,575,629 F1 · kind: On July 31, 2024, Title 19 Promis acquired 465,116 units, each consisting of (a) one Common Share, (b) one Tranche A Common Share purchase warrant, (c) one Tranche B Common Share purchase warrant and (iv) one Tranche C Common Share purchase warrant, in a private placement the ("Offering") conducted by the Issuer. The purchase price for each Unit was $2.15 per Unit. F1 · price: On July 31, 2024, Title 19 Promis acquired 465,116 units, each consisting of (a) one Common Share, (b) one Tranche A Common Share purchase warrant, (c) one Tranche B Common Share purchase warrant and (iv) one Tranche C Common Share purchase warrant, in a private placement the ("Offering") conducted by the Issuer. The purchase price for each Unit was $2.15 per Unit. F2 · ownership.nature: By Title 19 Promis, a series of a Delaware limited liability company, of which the Reporting Person is the sole manager. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.